Meyka Pro banner
argenx SE

argenx SE (ARGX) Stock Overview

Explore argenx SE’s financial performance, market position, analyst ratings, and future outlook.

ARGXNASDAQ
HealthcareBiotechnology
$990.54
$6.15(0.62%)
U.S. Market opens in NaNh NaNm

argenx SE (ARGX)

Meyka AI Score

Z

Key Financials

Market Cap61.6B
P/E Ratio35.66
EPS (TTM)$11.08
ROE0.24%
Fundamental Analysis

AI Price Forecasts

1 Month$1077.89
3 Months$1123.18
1 Year Target$891.55

ARGX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of argenx SE (NASDAQ: ARGX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, argenx SE's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ARGX on the NASDAQ shows an RSI of 51.81, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $891.55 for the NASDAQ listing.

Key metrics behind argenx SE's NASDAQ-traded stock include a P/E ratio of 35.66 and a market capitalization of 61.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ARGX on the NASDAQ.

Price Performance (NASDAQ: ARGX)

1-Day Change
0.62%
5-Day Change
-0.11%
1-Month Change
16.36%
3-Month Change
10.86%
6-Month Change
41.41%
Year-to-Date (YTD) Change
17.79%
1-Year Change
30.88%
3-Year Change
89.26%
5-Year Change
207.62%
All-Time (Max) Change
4206.70%

Contact Information

31 10 703 8441
Laarderhoogtweg 25, Amsterdam, NH, 1101 EB

Company Facts

18,630 Employees
IPO DateMay 18, 2017
CountryNL
Actively Trading

Frequently Asked Questions